Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1823]
News [2731]
Articles [202]
Editorials [1]
Conferences [136]
elearning [13]
SABCS 2019: Addition of S-1 to post-operative endocrine therapy improves outcomes for patients with hormone receptor-positive, HER2-negative breast cancer
SABCS 2019: Addition of S-1 to post-operative endocrine therapy improves outcomes for patients with hormone...
ASH 2019: New drug markedly improves overall survival in patients with AML in remission
ASH 2019: New drug markedly improves overall survival in patients with AML in remission
ASH 2019: Immunotherapy superior to chemotherapy for children with relapsed B-ALL
ASH 2019: Immunotherapy superior to chemotherapy for children with relapsed B-ALL
ASH 2019: Novel immunotherapy agent for multiple myeloma shows promising pre-clinical results
ASH 2019: Novel immunotherapy agent for multiple myeloma shows promising pre-clinical results
ASH 2019: CAR-T immunotherapy shows success and reduces health care utilisation in older patients
ASH 2019: CAR-T immunotherapy shows success and reduces health care utilisation in older patients
ASH 2019: Dual-targeted antibody elicits durable responses in poor-prognosis non-Hodgkin Lymphoma
ASH 2019: Dual-targeted antibody elicits durable responses in poor-prognosis non-Hodgkin Lymphoma
ASH 2019: High response rate seen with BCMA-directed CAR T-cell therapy for multiple myeloma
ASH 2019: High response rate seen with BCMA-directed CAR T-cell therapy for multiple myeloma
ASH 2019: Encouraging results for dual-targeted CAR T-cell therapy in hard-to-treat multiple myeloma
ASH 2019: Encouraging results for dual-targeted CAR T-cell therapy in hard-to-treat multiple myeloma
New prognostic markers for triple negative breast cancer confirmed
New prognostic markers for triple negative breast cancer confirmed
FDA approves atezolizumab with nab-paclitaxel and carboplatin for metastatic NSCLC without EGFR/ALK aberrations
FDA approves atezolizumab with nab-paclitaxel and carboplatin for metastatic NSCLC without EGFR/ALK aberrations

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation